A4M and the International Peptide Society Welcome PCAC Recommendations Supporting Inclusion of Six Reviewed Peptides on the 503A Bulk List

Source Summary

This advisory vote marks a pivotal step toward advancing a regulated, evidence-informed compounding pathway for patients and providers to access clinically important peptides. This advisory vote marks a pivotal step toward advancing a regulated, evidence-informed compounding pathway for patients and providers to access clinically important peptides.